Additional Proxy Soliciting Materials (definitive) (defa14a)
July 13 2021 - 8:28AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934
(Amendment No. _)
Filed by the Registrant ☒
|
|
Filed by a Party other than the Registrant ☐
|
☐
|
Preliminary Proxy Statement
|
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
☐
|
Definitive Proxy Statement
|
|
|
☒
|
Definitive Additional Materials
|
|
|
☐
|
Soliciting Material Pursuant to §240.14a-12
|
ADAMIS PHARMACEUTICALS CORPORATION
(Name of Registrant as Specified In Its Charter)
Not Applicable
(Name of Person(s) Filing Proxy Statement, if other
than Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
☒
|
No fee required.
|
|
|
☐
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total fee paid:
|
|
|
|
☐
|
Fee paid previously with preliminary materials.
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for
which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or
Schedule and the date of its filing.
|
|
|
|
|
(1)
|
Amount Previously Paid:
|
|
|
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing Party:
|
|
|
|
|
(4)
|
Date Filed:
|
|
|
|
Adamis Urges Stockholders
to Vote to Reelect the Company’s Board of Directors at
Upcoming Annual Meeting on Friday, July 16th
SAN
DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged
its valued stockholders to vote to reelect all five members of the Company’s Board of Directors (the “Board”) at the
upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on July 16, 2021. In addition, the Board issued the following
statement:
“Ahead
of this year’s Annual Meeting, the Board prioritized engaging with stockholders and gathering feedback regarding the Company’s
governance, operational priorities and overall strategy. We very much appreciate that a large cross-section of stockholders ultimately
provided their candid viewpoints to us and our representatives. The Board is committed to factoring these important views into its go-forward
plans. While the road to value creation in the biotechnology and pharmaceutical industries is often bumpy, we firmly believe that Adamis
now has tangible pipeline momentum that can be built on over the next year. The Board will focus on putting stockholders’ interests
first and making decisions that can position Adamis to become a source of enduring value for investors, patients, providers and society
as a whole.”
For more information about the Company’s strategic priorities and high-potential pipeline, please view our updated investor presentation
here.
About
Adamis Pharmaceuticals
Adamis
Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in
various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI (epinephrine)
Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’
naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing
additional products, including treatments for acute respiratory diseases, such as COVID-19, and radiation dermatitis. The company’s
subsidiary, US Compounding Inc. (“USC”), compounds sterile prescription drugs, and certain nonsterile drugs for human and
veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information
about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.
Forward
Looking Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise
are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited
to the following statements: the Company’s beliefs concerning the safety and effectiveness of Tempol and the Company’s other
product candidates; the timing of commencement or completion of any studies or trials relating to Tempol and the availability of funding
for studies or trials; the results of any studies or trials that the Company may conduct relating to Tempol; the Company’s ability
to successfully commercialize the products and product candidates described in this press release, itself or through commercialization
partners, and the Company’s beliefs concerning the commercial success of its products; future regulatory actions relating to the
Company’s New Drug Application (“NDA”) relating to its ZIMHI product; the Company’s beliefs concerning the benefits,
enforceability, and extent of intellectual property protection afforded by patents and patent applications that it owns or has licensed
and its rights under applicable license agreements, and its ability to enforce its patents and other intellectual property rights against
third parties; the Company’s expectations concerning future growth; expectations and statements about the Company’s strategies,
objectives, future goals and achievements; and other statements concerning our future operations, activities and financial results. These
statements are only predictions and
involve
known and unknown risks, uncertainties, and other factors, which may cause Adamis’ actual results to be materially different from
the results anticipated by such forward-looking statements. There can be no assurances regarding the outcome of trials or studies relating
to Tempol or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. There can be no
assurances that future sales of SYMJEPI will meet our expectations. There can be no assurances regarding the timing or outcome of the
FDA’s review of our resubmitted NDA relating to ZIMHI, or that the Company will be able to successfully take any actions or develop
any additional information that the FDA may require in connection with its review of the resubmitted NDA for ZIMHI. There can be no assurances
that the FDA will consider the Company’s responses included in the resubmitted NDA relating to ZIMHI as satisfactory, or that the
product will be able to compete successfully in the market if approved and launched. The Company may not achieve one or more of the future
goals described in the press release either within the anticipated time periods or at all. In addition, as previously disclosed, each
of the Company and USC previously received a subpoena from the U.S. Attorney’s Office for the Southern District of New York issued
in connection with a criminal investigation. Accordingly, all forward-looking statements are subject to the outcome of this investigation,
as well as the related investigation being conducted by the Company’s Audit Committee. We cannot assess the impact of each factor
on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking
statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation
to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances
arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described
in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended
December 31, 2020 and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available
free of charge on the SEC's web site at http://www.sec.gov.
Contacts
Saratoga
Proxy Consulting
John
Ferguson / Ann Marie Mellone, 212-257-1311
jferguson@saratogaproxy.com / amellone@saratogaproxy.com
MKA
Greg Marose, 646-386-0091
gmarose@mkacomms.com
###
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024